Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Cefiderocol vs. Ceftolozane: In Vitro Susceptibility in Resi

    2026-04-20

    Comparative In Vitro Activity of Cefiderocol Against Resistant Enterobacterales: Implications for PK/PD Modeling and Antibacterial Testing Workflows

    Study Background and Research Question

    Antimicrobial resistance among Enterobacterales, especially to carbapenems and advanced β-lactam/β-lactamase inhibitor combinations, presents a significant clinical challenge across Europe. The World Health Organization has designated carbapenem-resistant Enterobacterales (CREs) as critical priority pathogens due to limited therapeutic options and rising resistance rates (source: paper). The referenced study aimed to systematically examine the in vitro efficacy of cefiderocol—a siderophore cephalosporin with a unique iron-uptake mechanism—against a large cohort of European Enterobacterales, focusing on isolates resistant to both meropenem and newer β-lactam/β-lactamase inhibitor combinations. This context is highly relevant for researchers modeling resistance or optimizing antibacterial susceptibility workflows.

    Key Innovation from the Reference Study

    The principal innovation of this research lies in its comprehensive, head-to-head comparison of cefiderocol with both approved and developmental β-lactam/β-lactamase inhibitor combinations. By leveraging a robust, multi-country isolate collection (n = 1,909), the study directly quantifies the in vitro susceptibility landscape for CREs—including those harboring diverse resistance determinants—and provides actionable data on the relative potency of cefiderocol, aztreonam-avibactam, cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and others (source: paper).

    Methods and Experimental Design Insights

    Researchers collected Enterobacterales isolates from hospitalized patients in 49 sites across six European countries over a one-year period (2020). The isolate panel comprised Klebsiella spp. (n = 970), Escherichia coli (n = 382), and Enterobacter spp. (n = 244), with bloodstream infections representing the most common source (43.6%). Susceptibility testing was performed using standardized in vitro antibacterial susceptibility assays, with MIC breakpoints aligned to high-dose clinical regimens (e.g., meropenem MIC >8 mg/L defined resistance). Molecular analysis via PCR and whole-genome sequencing characterized resistance mechanisms, particularly in cefiderocol-resistant isolates (source: paper).

    Protocol Parameters

    • assay: in vitro antibacterial susceptibility assay | value_with_unit: MIC determination (range 0.03–32 mg/L) | applicability: Enterobacterales including carbapenem-resistant isolates | rationale: Quantifies drug activity across resistance profiles | source_type: paper
    • assay: in vivo infection model | value_with_unit: neutropenic mouse thigh infection model | applicability: PK/PD target validation for bactericidal agents | rationale: Bridges in vitro MIC to therapeutic efficacy | source_type: workflow_recommendation
    • assay: molecular resistance mechanism analysis | value_with_unit: PCR, whole-genome sequencing | applicability: Isolates with reduced cefiderocol susceptibility | rationale: Identifies β-lactamase and iron-uptake mutations | source_type: paper
    • assay: in vitro susceptibility testing ceftolozane | value_with_unit: cation-adjusted Mueller-Hinton broth; 0.03–32 mg/L | applicability: Pseudomonas aeruginosa, Enterobacterales | rationale: Standardized comparison with cefiderocol and others | source_type: product_spec

    Core Findings and Why They Matter

    Among all Enterobacterales tested, cefiderocol demonstrated an overall susceptibility rate of 98.1%, surpassing available β-lactam/β-lactamase inhibitor combinations (range: 78.1%–97.4%) and closely matching developmental agents such as cefepime-taniborbactam and aztreonam-avibactam (98.7%–99.1%) (source: paper). In the subset of meropenem-resistant isolates (n = 148), cefiderocol maintained 87.8% susceptibility, sharply exceeding the 0%–71.6% rates observed for other approved combinations (source: paper). For isolates resistant to both meropenem and β-lactam/β-lactamase inhibitor combinations, cefiderocol was active against 61.9%–65.9%, while alternatives were far less effective (0%–20.5%). Genotypic analysis revealed that most meropenem-resistant isolates carried Klebsiella pneumoniae carbapenemase (KPC) genes, while metallo-β-lactamases (MBLs) and OXA carbapenemases were less prevalent. Importantly, cefiderocol retained activity against most β-lactamase producers except for NDM (a prominent MBL), AmpC, and non-carbapenemase OXA producers. Cefiderocol-resistant isolates frequently showed complex resistance mechanisms, including multiple iron-uptake pathway mutations, carbapenemase genes, and ftsI mutations (source: paper). The study emphasizes the value of early, parallel susceptibility testing—including cefiderocol and comparator agents—to enable evidence-based selection of optimal therapy, particularly when facing multidrug-resistant or metallo-β-lactamase-producing strains (source: paper).

    Comparison with Existing Internal Articles

    Relevant internal resources, such as "Ceftolozane Sulfate: Optimizing Workflows for Resistant Pathogens," provide detailed guidance on deploying Ceftolozane sulfate in both in vitro and in vivo models, with a particular focus on Pseudomonas aeruginosa and experimental design for pharmacokinetic/pharmacodynamic (PK/PD) studies. While the reference paper centers on Enterobacterales and cefiderocol, the underlying methodologies—including susceptibility testing, MIC determination, and resistance mechanism analysis—are directly transferable. Both resources converge on the importance of standardized protocols and robust phenotypic/genotypic correlation for accurate resistance modeling.

    Limitations and Transferability

    Although the study features a large, geographically diverse collection and rigorous molecular characterization, its conclusions are inherently bound to in vitro activity, which may not fully predict clinical efficacy in all patient populations. Additionally, some resistance mechanisms (notably NDM-type MBLs) diminish cefiderocol’s potency, and the study's design does not address the translation of in vitro MICs to in vivo outcomes or dosing regimens. Therefore, researchers should integrate susceptibility data with PK/PD modeling—such as those described for Ceftolozane sulfate in neutropenic mouse thigh infection models—for translational validation (source: workflow_recommendation).

    Research Support Resources

    For researchers aiming to replicate or extend these antibacterial susceptibility workflows, the use of standardized agents such as Ceftolozane sulfate (SKU C8753) is recommended, particularly for in vitro and in vivo PK/PD studies relevant to Pseudomonas aeruginosa and non-carbapenemase-producing Enterobacterales. APExBIO provides detailed product specifications and storage guidance to ensure experimental fidelity. Integrating these resources with evidence-based protocols will enhance the robustness and clinical relevance of resistance modeling and antibacterial efficacy studies.